STERIS(STE) Newsfilter·2025-02-05 21:30Core Insights - STERIS plc reported a 6% increase in total revenue from continuing operations for Q3 fiscal 2025, reaching $1.4 billion compared to $1.3 billion in Q3 fiscal 2024 [1][8] - The company updated its fiscal 2025 outlook, expecting revenue growth of approximately 6%, down from previous expectations of 6.5% to 7.5% due to unfavorable currency rates and lower anticipated capital equipment revenue [7] Financial Performance - Net income for Q3 fiscal 2025 was $173.6 million, or $1.75 per diluted share, up from $148.4 million, or $1.49 per diluted share in Q3 fiscal 2024 [2] - Adjusted net income for Q3 fiscal 2025 was $229.1 million, or $2.32 per diluted share, compared to $207.6 million, or $2.09 per diluted share in the same period last year [2] Segment Performance - Healthcare revenue grew 7% to $976.0 million in Q3 fiscal 2025, driven by a 9% increase in consumable revenue and a 13% rise in service revenue, despite a 5% decline in capital equipment revenue [3] - Applied Sterilization Technologies (AST) revenue increased 10% to $258.1 million, with service revenue also growing by 10% [4] - Life Sciences revenue decreased 7% to $136.4 million, primarily due to the divestiture of the CECS business and a decline in capital equipment revenue, although consumable revenue grew by 14% [5] Cash Flow and Outlook - Net cash provided by operations for the first nine months of fiscal 2025 was $887.3 million, up from $718.5 million in the same period of fiscal 2024 [6] - Free cash flow for the first nine months of fiscal 2025 was $588.1 million, compared to $457.0 million in the prior year [6] - The company anticipates capital expenditures of approximately $360 million and free cash flow of around $700 million for fiscal 2025 [9]